Hunan Fangsheng Pharmaceutical Co., Ltd. (SHA:603998)
9.69
-0.24 (-2.42%)
Nov 13, 2026, 3:00 PM CST
SHA:603998 Revenue
Hunan Fangsheng Pharmaceutical had revenue of 426.45M CNY in the quarter ending September 30, 2026, with 1.76% growth. This brings the company's total for the last twelve months to 1.88B, up 11.56% year-over-year. In the year 2025, Hunan Fangsheng Pharmaceutical had annual revenue of 1.75B, down -1.75%. That makes Hunan Fangsheng Pharmaceutical the 14,991st largest company in the world by revenue and 2,694th in China.
Revenue (ttm)
1.88B
Revenue Growth
+11.56%
P/S Ratio
2.27
Revenue / Employee
1.00M
Employees
1,868
Market Cap
4.25B
Revenue by Segment
- Pharmaceutical Manufacturing Business 1.65B 94.9%
- Other 88.41M 5.1%
Fiscal year ended Dec 31, 2025 See the full SHA:603998 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.75B | -31.05M | -1.75% |
| Dec 31, 2024 | 1.78B | 148.95M | 9.15% |
| Dec 31, 2023 | 1.63B | -163.46M | -9.12% |
| Dec 31, 2022 | 1.79B | 225.03M | 14.36% |
| Dec 31, 2021 | 1.57B | 288.21M | 22.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jianmin Pharmaceutical Group | 3.12B |
| Luoxin Pharmaceuticals Group Stock | 2.23B |
| Fuan Pharmaceutical (Group) | 1.65B |
| Guizhou Sanli Pharmaceutical Co.,Ltd | 1.64B |
| Shandong Wit Dyne Health | 1.51B |
| Beijing Beilu Pharmaceutical | 1.39B |
| Hunan Hansen Pharmaceutical | 1.01B |
| Teyi Pharmaceutical Group Co.,Ltd | 856.22M |